BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. Medicine (Baltimore). 2018;97:e11518. [PMID: 30075518 DOI: 10.1097/md.0000000000011518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Z, Li Y, Fan S, An J, Luo X, Liang M, Zhu F, Huang K. WW domain-binding protein 2 overexpression prevents diet-induced liver steatosis and insulin resistance through AMPKβ1. Cell Death Dis 2021;12:228. [PMID: 33658485 DOI: 10.1038/s41419-021-03536-8] [Reference Citation Analysis]
2 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020; 12(12): 1168-1181 [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Altshuler PJ, Dang H, Frank AM, Shah AP, Glorioso J, Zhan T, Rios Diaz A, Shaheen O, Ramirez CB, Maley WR, Bodzin AS. Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis. Liver Transpl 2021. [PMID: 34564931 DOI: 10.1002/lt.26313] [Reference Citation Analysis]
4 Zou B, Yeo YH, Jeong D, Park H, Sheen E, Lee DH, Henry L, Garcia G, Ingelsson E, Cheung R, Nguyen MH. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. Dig Dis Sci 2020;65:1520-8. [PMID: 31598919 DOI: 10.1007/s10620-019-05869-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
5 Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care 2021;44:399-406. [PMID: 33355256 DOI: 10.2337/dc20-1997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
6 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Thongtan T, Deb A, Vutthikraivit W, Laoveeravat P, Mingbunjerdsuk T, Islam S, Islam E. Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Indian J Gastroenterol. [DOI: 10.1007/s12664-021-01230-3] [Reference Citation Analysis]
8 Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatol Commun 2020;4:1637-50. [PMID: 33163834 DOI: 10.1002/hep4.1581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
9 Philip G, Hookey L, Richardson H, Flemming JA. Alcohol-associated Liver Disease Is Now the Most Common Indication for Liver Transplant Waitlisting Among Young American Adults. Transplantation 2022. [PMID: 35642977 DOI: 10.1097/TP.0000000000004202] [Reference Citation Analysis]
10 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Sayiner M, Stepanova M, De Avila L, Golabi P, Racila A, Younossi ZM. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Dig Dis Sci 2020;65:416-22. [PMID: 31451982 DOI: 10.1007/s10620-019-05786-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Jothimani D, Danielraj S, Narasimhan G, Kaliamoorthy I, Rajakumar A, Palaniappan K, Palanichamy S, Rammohan A, Ramachandran H, Rajalingam R, Rela M. Nonalcoholic Steatohepatitis: A Rapidly Increasing Indication for Liver Transplantation in India. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Sci Rep 2019;9:9046. [PMID: 31227742 DOI: 10.1038/s41598-019-45178-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
14 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Reference Citation Analysis]
15 Samji NS, Heda R, Satapathy SK. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . Transl Gastroenterol Hepatol 2020;5:10. [PMID: 32190778 DOI: 10.21037/tgh.2019.09.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 de Avila V, Paik JM, de Avila L, Henry L, Mohess D, Roche-Green A, Younossi ZM. Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. JHEP Rep 2021;3:100236. [PMID: 33748729 DOI: 10.1016/j.jhepr.2021.100236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Huang Z, Wu LM, Zhang JL, Sabri A, Wang SJ, Qin GJ, Guo CQ, Wen HT, Du BB, Zhang DH, Kong LY, Tian XY, Yao R, Li YP, Liang C, Li PC, Wang Z, Guo JY, Li L, Dong JZ, Zhang YZ. Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways. Hepatology 2019;70:1099-118. [PMID: 30820969 DOI: 10.1002/hep.30597] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
18 Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. Hepatol Commun 2019;3:1459-71. [PMID: 31701070 DOI: 10.1002/hep4.1419] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
19 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Coman LI, Coman OA, Bădărău IA, Păunescu H, Ciocîrlan M. Association between Liver Cirrhosis and Diabetes Mellitus: A Review on Hepatic Outcomes. J Clin Med 2021;10:E262. [PMID: 33445629 DOI: 10.3390/jcm10020262] [Reference Citation Analysis]